I did a whole article on FDA CBER Director Dr Peter Marks’ talk where he focused exclusively on the potential for gene therapy and the FDA’s commitment to it. There is optimism and positive ...

Vinay Prasad will replace Marks as CBER director Trump's budget would be "catastrophic" for federal R&D Pharma still in waiting mode after UK-US trade agreement ...

In this article, Yanis Saradijan discusses the role of medical science liaisons, using statistics from a recent study of MSLs to comment on the trends in MSL management since their creation in the ...

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients. IntraBio's ...

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first approved ...